Key result
Direct oral anticoagulants offer pharmacologic advantages over vitamin K antagonists, including a wider therapeutic window and rapid onset, for preventing stroke and treating venous thromboembolism.
Why the study?
Do direct oral anticoagulants offer advantages over vitamin K antagonists in patients requiring anticoagulation?
Do direct oral anticoagulants offer advantages over vitamin K antagonists in patients requiring anticoagulation?
Direct oral anticoagulants provide pharmacologic advantages over vitamin K antagonists for stroke prevention in atrial fibrillation and VTE management.
No takes yet. Share an insight, caveat, or question.
May support DOAC preference for stroke prevention and VTE; leaves open need for higher-level comparative data in special populations.
Kenneth A. Bauer (2015) conducted a review in Nonvalvular atrial fibrillation and venous thromboembolism. Direct oral anticoagulants vs. Vitamin K antagonists was evaluated. Direct oral anticoagulants offer pharmacologic advantages over vitamin K antagonists, including a wider therapeutic window and rapid onset, for preventing stroke and treating venous thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: